Effect of periodontal inflammatory on SARS-CoV-2 receptor expression

Effect of periodontal inflammatory on SARS-CoV-2 receptor expression - ParCov

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026710

Enrollment

200

Registered

2021-10-05

Start date

2021-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis stage II to IV, grade A to C

Interventions

Group 1: Periodontitis patients: stage II to IV, grade A to C The expression of SARS-CoV-2 receptors

ACE2, DPP4/CD26, CD39, CD73 and APN/CD13 is compared in oral mucosal cells from periodontitis patients with the expression in periodontally healthy individuals. Group 2: Subjects without periodontiti

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 10 own teeth Periodontitis patients: stage II to IV, grade A to C; Controls: no attachment loss detectable, probing depths (exclusion of pseudo-pockets) = 3 mm, bleeding on probing < 10%.

Exclusion criteria

Exclusion criteria: Systemic antibiotic therapy and subgingival periodontal therapy in the last 6 months; pregnancy; general diseases with known association to periodontitis, (e.g. diabetes mellitus type I/II, coronary heart disease), medication leading to hyperplasia.

Design outcomes

Primary

Measure	Time frame
Determination of SARS-CoV-2 receptor expression; ACE2, DPP4/CD26, CD39, CD73, and APN/CD13.	—

Secondary

Measure	Time frame
Genotyping of the SARS-CoV-2 receptors. ACE2, DPP4/CD26, CD39, CD73, and APN/CD13.	—

Countries

Germany

Contacts

Public ContactSusanne Schulz

Martin-Luther-Universität Halle-Wittenberg Universitätspoliklinik für Zahnerhaltungskunde und Parodontologie

susanne.schulz@medizin.uni-halle.de+49-345-557 1147

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026